Product Development Pipeline
Product Candidate
Signaling Activation
Indication
Discovery
Lead Optimization
IND-Enabling
Phase 1
Deep IL-15
Solid & hematologic tumors
Deep TLR/STING
Solid tumors
Deep IL-12
Solid tumors
Deep Checkpoint Inhibitor
Solid & hematologic tumors
autocrine
paracrine

Torque is developing a new class of Deep-Primed™ immune cell therapeutics for the treatment of cancer. We use a technology platform to anchor powerful biotherapeutics—stimulatory cytokines, antibodies, and small molecules—directly to immune cells to direct and evoke immune cell responses, locally in the tumor microenvironment.

We currently have active programs targeting multiple different immunomodulatory drugs that are both autocrine and paracrine activators. Deep IL-15 is advancing toward the first clinical trials in mid-2018 for both hematologic and solid tumors. We are also advancing small-molecule TLR/STING agonists and Deep IL-12, which both target innate immunity to amplify the immune response for durability and memory. In addition, we are pursuing several approaches to develop Deep Checkpoint Inhibition.

Back to Top